当前位置:首页 - 行情中心 - 浙江医药(600216) - 财务分析 - 现金流量表

浙江医药

(600216)

  

流通市值:135.48亿  总市值:136.94亿
流通股本:9.51亿   总股本:9.62亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,103,549,287.059,008,442,586.917,005,114,859.744,504,384,317.32
  收到的税费返还82,465,625.54417,886,143.15398,671,381.35345,238,593.73
  收到其他与经营活动有关的现金23,568,085.16131,107,086.65113,340,958.0183,503,024.92
  经营活动现金流入小计2,209,582,997.759,557,435,816.717,517,127,199.14,933,125,935.97
  购买商品、接受劳务支付的现金1,259,867,312.614,655,661,305.813,681,699,974.682,406,085,754.18
  支付给职工以及为职工支付的现金347,557,871.83977,201,556.15774,221,238.49566,846,592.13
  支付的各项税费230,010,525.87815,944,497.28698,622,952.68545,984,460.13
  支付其他与经营活动有关的现金272,131,480.941,222,859,746.2873,917,259.34616,027,924.49
  经营活动现金流出小计2,109,567,191.257,671,667,105.446,028,461,425.194,134,944,730.93
  经营活动产生的现金流量净额100,015,806.51,885,768,711.271,488,665,773.91798,181,205.04
二、投资活动产生的现金流量:
  收回投资收到的现金356,526,269.31,267,448,330.49824,723,419.38419,142,568.18
  取得投资收益收到的现金60,000713,015.21500,558.14417,234.54
  处置固定资产、无形资产和其他长期资产收回的现金净额59,5001,865,875.011,161,360.29327,832
  收到的其他与投资活动有关的现金150,421,531.13848,065,067.62695,205,845.38489,559,410.93
  投资活动现金流入小计507,067,300.432,118,092,288.331,521,591,183.19909,447,045.65
  购建固定资产、无形资产和其他长期资产支付的现金167,379,534.18446,471,610.05288,220,093.07208,193,588.87
  投资支付的现金576,203,507.321,261,067,492.56838,899,992.56425,781,417.86
  支付其他与投资活动有关的现金150,000,000782,500,000637,500,000402,500,000
  投资活动现金流出小计893,583,041.52,490,039,102.611,764,620,085.631,036,475,006.73
  投资活动产生的现金流量净额-386,515,741.07-371,946,814.28-243,028,902.44-127,027,961.08
三、筹资活动产生的现金流量:
  吸收投资收到的现金41,100,000---
  其中:子公司吸收少数股东投资收到的现金41,100,000---
  取得借款收到的现金300,000,000695,000,000546,577,625.82495,000,000
  收到其他与筹资活动有关的现金-74,781,200--
  筹资活动现金流入小计341,100,000769,781,200546,577,625.82495,000,000
  偿还债务支付的现金209,000,000577,000,000341,500,000338,000,000
  分配股利、利润或偿付利息支付的现金4,763,445.88376,692,920.16370,696,311.3411,848,151.42
  支付其他与筹资活动有关的现金-218,950,936.68202,029,611.85136,919,330
  筹资活动现金流出小计213,763,445.881,172,643,856.84914,225,923.19486,767,481.42
  筹资活动产生的现金流量净额127,336,554.12-402,862,656.84-367,648,297.378,232,518.58
四、汇率变动对现金及现金等价物的影响-30,817,344.9290,287,386.8855,426,355.6863,636,449.18
五、现金及现金等价物净增加额-189,980,725.371,201,246,627.03933,414,929.78743,022,211.72
  加:期初现金及现金等价物余额3,166,832,038.091,965,585,411.061,965,585,411.061,965,585,411.06
  期末现金及现金等价物余额2,976,851,312.723,166,832,038.092,899,000,340.842,708,607,622.78
补充资料:
  净利润-760,239,195-624,571,156.24
  资产减值准备-202,120,062.39-79,707,143.85
  固定资产和投资性房地产折旧-693,793,030.97-340,383,586.5
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-693,793,030.97-340,383,586.5
  无形资产摊销-98,905,655.78-41,490,056.32
  长期待摊费用摊销-4,463,475.09-2,246,163.14
  处置固定资产、无形资产和其他长期资产的损失-81,154.73--178,709.95
  固定资产报废损失-6,478,423.46-1,132,404
  公允价值变动损失--4,642,415.19--1,276,670.78
  财务费用--50,099,758.19--90,577,420.59
  投资损失--2,847,078.19-3,372,533.17
  递延所得税--493,100.39--19,334,508.99
  其中:递延所得税资产减少--493,100.39--19,334,508.99
  存货的减少-32,699,842.33--179,104,430.32
  经营性应收项目的减少-144,042,273.57-250,080,707.79
  经营性应付项目的增加--6,169,282.34--249,561,761.6
  其他-11,897,682.86--
  现金的期末余额-3,166,832,038.09-2,708,607,622.78
  减:现金的期初余额-1,965,585,411.06-1,965,585,411.06
  现金及现金等价物的净增加额-1,201,246,627.03-743,022,211.72
公告日期2026-04-242026-04-112025-10-282025-08-26
审计意见(境内)标准无保留意见
TOP↑